Jason Aryeh

Director Jason Aryeh sold 5,000 shares of LGND for $1,250,000.00 in two transactions at $250.00

Jason Aryeh, a Director at Ligand Pharmaceuticals, executed 2 separate sales totaling 5,000 shares for $1,250,000.00 on 2026-06-10 and 2026-06-11 at $250.00, reducing his non-derivative holdings from 107,580 to 102,580 shares (-4.6% of pre-transaction holdings). The sales occurred near the 52-week high of $259.03, with the stock at $255.54 currently and up 15.5% over 30 days and 25.9% over 90 days, providing favorable pricing context. Aryeh retains 2,938 shares in non-qualified stock options and maintains significant ongoing exposure through derivative holdings. His prior 3 sales at LGND showed 90-day returns of +16.2%, +15.8%, and +15.1%, indicating his past sales at this ticker did not precede stock declines, though this partial sale does not signal full-position exit given remaining derivative holdings.

Director Aryeh Jason bought 8,971 shares of OBIO at $3.90 on 2026-05-15; prior buy at same ticker returned +77.1% in 90 days

Aryeh Jason, a Director at Orchestra BioMed Holdings (OBIO), purchased 8,971 shares at $3.90 on 2026-05-15 for $34,986.90, increasing his holdings by 8.3%. This buy mirrors a prior open-market purchase at OBIO on 2025-09-19, which delivered a +77.1% 90-day return. His cross-ticker buy history shows 1 prior buy with an avg 30d return of +35.5% and avg 90d return of +77.1%, with a 100.00% win rate on the 90-day mark. However, the stock is currently down -12.7% over the past 30 days and down -26.2% from its 52-week high of $5.42, suggesting the timing of this purchase relative to recent momentum warrants attention. The company remains unprofitable with net income of $-20.7M against revenue of $110.0K, though it recorded exceptional annual revenue growth of +1169.2%.

Director Aryeh Jason sold 10,000 shares for $1.7M at $170.81 blended average, retaining 69.3K shares.

Aryeh Jason (Director) executed 3 separate sales on 2025-09-23 totaling 10,000 shares for $1,708,087.72 at a blended average price of $170.81. The stock currently trades at $168.96, below the transaction prices. Jason's post-transaction holdings of 69.3K shares represent 12.6% of his prior position, a material but not extraordinary reduction in his stake. His cross-ticker track record shows only 1 prior buy, offering limited context for assessing his historical sell patterns. The company is growing revenue at +27.3% year-over-year but remains unprofitable on a full-year basis, creating a mixed fundamental backdrop. This transaction occurred near the stock's 52-week high of $170.77 and after strong 30-day and 90-day gains, but the filing itself contains no indication of scheduled plan participation or timing constraints.

Director Aryeh Jason buys 1,000 shares of OBIO at $2.45 as stock trades -61.6% from 52-week high.

Aryeh Jason, a director of Orchestra BioMed Holdings, purchased 1,000 shares at $2.45 on 2025-09-19, increasing his holdings from 107,482 to 108,482 shares. The transaction occurs in a context of significant distress: the company is unprofitable with a net loss of $-19.4M over the most recent full fiscal year, quarterly revenue has contracted year-over-year by 4.4%, and the stock is trading at $2.44, down 61.6% from its 52-week high of $6.36. The modest purchase size (1,000 shares, representing a 0.9% increase in his holdings) during a period of acute operational headwinds warrants monitoring but does not constitute material conviction evidence. The transaction is observable but requires context on whether this represents routine portfolio management or a broader pattern of board-level support during financial stress.